DE69528475D1 - Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie - Google Patents
Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgieInfo
- Publication number
- DE69528475D1 DE69528475D1 DE69528475T DE69528475T DE69528475D1 DE 69528475 D1 DE69528475 D1 DE 69528475D1 DE 69528475 T DE69528475 T DE 69528475T DE 69528475 T DE69528475 T DE 69528475T DE 69528475 D1 DE69528475 D1 DE 69528475D1
- Authority
- DE
- Germany
- Prior art keywords
- serotonin antagonists
- treating fibromyalgia
- fibromyalgia
- antagonists
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9406857A GB9406857D0 (en) | 1994-04-07 | 1994-04-07 | Improvements in or relating to organic compounds |
PCT/EP1995/001264 WO1995027490A1 (en) | 1994-04-07 | 1995-04-06 | Use of serotonin antagonists (5ht3) for treating fibromyalgia |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69528475D1 true DE69528475D1 (de) | 2002-11-07 |
DE69528475T2 DE69528475T2 (de) | 2003-02-20 |
Family
ID=10753131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69528475T Expired - Lifetime DE69528475T2 (de) | 1994-04-07 | 1995-04-06 | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie |
Country Status (22)
Country | Link |
---|---|
US (2) | US5773436A (de) |
EP (1) | EP0804196B1 (de) |
JP (1) | JP2818303B2 (de) |
KR (1) | KR100415181B1 (de) |
CN (1) | CN1084618C (de) |
AT (1) | ATE225176T1 (de) |
AU (1) | AU706279B2 (de) |
CA (1) | CA2186844C (de) |
CZ (1) | CZ290359B6 (de) |
DE (1) | DE69528475T2 (de) |
DK (1) | DK0804196T3 (de) |
ES (1) | ES2184797T3 (de) |
FI (1) | FI118034B (de) |
GB (1) | GB9406857D0 (de) |
HU (1) | HU226892B1 (de) |
MX (1) | MX9604589A (de) |
NO (1) | NO312745B1 (de) |
PL (1) | PL316658A1 (de) |
PT (1) | PT804196E (de) |
RU (1) | RU2165760C2 (de) |
SK (1) | SK281603B6 (de) |
WO (1) | WO1995027490A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0914322A1 (de) * | 1996-05-27 | 1999-05-12 | Fujisawa Pharmaceutical Co., Ltd. | Neue indolyl und benzofuranylcarboxamide als inhibitoren der stickoxidproduktion |
US6696495B2 (en) | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
WO2000048597A1 (en) | 1999-02-18 | 2000-08-24 | Novartis Ag | Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes |
EP1152761B1 (de) * | 1999-02-18 | 2009-06-24 | Novasearch AG | Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen |
TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
GB9918425D0 (en) * | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
KR100614900B1 (ko) | 2001-10-02 | 2006-08-25 | 파마시아 앤드 업존 캄파니 엘엘씨 | 질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물 |
WO2003032897A2 (en) * | 2001-10-16 | 2003-04-24 | Astrazeneca Ab | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
JP2005523288A (ja) | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾病治療用の縮合した二環式−n−架橋−複素環式芳香族カルボキサミド |
US6894042B2 (en) | 2002-02-19 | 2005-05-17 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
WO2003100091A1 (en) * | 2002-05-24 | 2003-12-04 | Epidauros Biotechnologie Ag | Means and methods for improved treatment using 'setrones' |
MXPA05003317A (es) * | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
WO2004062623A2 (en) * | 2003-01-13 | 2004-07-29 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
MXPA05007379A (es) * | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos. |
BRPI0417323A (pt) * | 2003-12-22 | 2007-03-27 | Memory Pharm Corp | indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos |
TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
US20050234095A1 (en) * | 2004-03-25 | 2005-10-20 | Wenge Xie | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
ATE487716T1 (de) * | 2004-04-22 | 2010-11-15 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen |
NZ551712A (en) * | 2004-05-07 | 2010-07-30 | Memory Pharm Corp | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof |
EP1807422B1 (de) * | 2004-11-05 | 2009-09-02 | Theravance, Inc. | 5-HT4-Rezeptoragonistenverbindungen |
JP5042028B2 (ja) * | 2004-11-05 | 2012-10-03 | セラヴァンス, インコーポレーテッド | キノリノン−カルボキサミド化合物 |
KR20070091665A (ko) * | 2004-12-22 | 2007-09-11 | 세라밴스 인코포레이티드 | 인다졸-카르복사미드 화합물 |
US7625924B2 (en) | 2004-12-22 | 2009-12-01 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
EA013567B1 (ru) * | 2005-03-02 | 2010-06-30 | Тереванс, Инк. | Хинолиноновые соединения в качестве агонистов рецептора 5-ht |
WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
WO2011055944A2 (en) * | 2009-11-06 | 2011-05-12 | Sk Holdings Co., Ltd. | Methods for treating fibromyalgia syndrome |
JOP20130213B1 (ar) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
PL3201203T3 (pl) | 2014-09-29 | 2021-11-22 | Takeda Pharmaceutical Company Limited | Krystaliczna postać 1-(1-metylo-1h-pirazol-4-ilo)-n-((1r,5s,7s)-9-metylo-3-oksa-9-azabicyklo[3.3.1]nonan-7-ylo)-1h-indolo-3-karboksyamidu |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8623142D0 (en) * | 1986-09-26 | 1986-10-29 | Beecham Group Plc | Compounds |
EP0200444B1 (de) * | 1985-04-27 | 1992-11-11 | Beecham Group Plc | Azabicyclononyl-indazol-carboxamid mit 5-HT-antagonistischer Wirkung |
-
1994
- 1994-04-07 GB GB9406857A patent/GB9406857D0/en active Pending
-
1995
- 1995-04-06 WO PCT/EP1995/001264 patent/WO1995027490A1/en active IP Right Grant
- 1995-04-06 DK DK95916611T patent/DK0804196T3/da active
- 1995-04-06 CA CA002186844A patent/CA2186844C/en not_active Expired - Fee Related
- 1995-04-06 CZ CZ19962915A patent/CZ290359B6/cs not_active IP Right Cessation
- 1995-04-06 SK SK1278-96A patent/SK281603B6/sk not_active IP Right Cessation
- 1995-04-06 ES ES95916611T patent/ES2184797T3/es not_active Expired - Lifetime
- 1995-04-06 HU HU9602721A patent/HU226892B1/hu not_active IP Right Cessation
- 1995-04-06 JP JP7526064A patent/JP2818303B2/ja not_active Expired - Fee Related
- 1995-04-06 AU AU23052/95A patent/AU706279B2/en not_active Ceased
- 1995-04-06 EP EP95916611A patent/EP0804196B1/de not_active Expired - Lifetime
- 1995-04-06 KR KR1019960705579A patent/KR100415181B1/ko not_active IP Right Cessation
- 1995-04-06 AT AT95916611T patent/ATE225176T1/de not_active IP Right Cessation
- 1995-04-06 CN CN95192946A patent/CN1084618C/zh not_active Expired - Fee Related
- 1995-04-06 RU RU96121561/14A patent/RU2165760C2/ru not_active IP Right Cessation
- 1995-04-06 US US08/721,988 patent/US5773436A/en not_active Expired - Lifetime
- 1995-04-06 DE DE69528475T patent/DE69528475T2/de not_active Expired - Lifetime
- 1995-04-06 PL PL95316658A patent/PL316658A1/xx unknown
- 1995-04-06 MX MX9604589A patent/MX9604589A/es not_active IP Right Cessation
- 1995-04-06 PT PT95916611T patent/PT804196E/pt unknown
-
1996
- 1996-10-04 NO NO19964236A patent/NO312745B1/no not_active IP Right Cessation
- 1996-10-04 FI FI964004A patent/FI118034B/fi not_active IP Right Cessation
-
1998
- 1998-05-18 US US09/080,605 patent/US5985866A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
DE59611411D1 (de) | Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz | |
ATE330630T1 (de) | Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose | |
DE69115921D1 (de) | Verfahren zur behandlung und verwendung von abfallstoffen | |
DE69524623T2 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
DE69621447D1 (de) | Verwendung von nitroflavonoide zur behandlung von angstzuständen | |
DE3856329D1 (de) | Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie | |
DE69007486D1 (de) | Verwendung von calciumantagonisten für die behandlung von narben. | |
DE69404725D1 (de) | Verfahren zur elektrolytischen Behandlung von Altbatterien | |
ATE203162T1 (de) | Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one | |
ATE25969T1 (de) | 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten. | |
DE69408394T2 (de) | 4-Piperidino-piperidin zur Behandlung von Tumoren | |
DE3785555T2 (de) | Verwendung von guaifenesin zur behandlung urologischer beschwerden. | |
DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
DE69711422D1 (de) | Verwendung von (r)-verapamil als medizin zur behandlung von angina | |
DE69926996D1 (de) | Verwendung von riluzol zur behandlung der retinalischemie | |
ATE209910T1 (de) | Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen | |
DE59102499D1 (de) | Verfahren zur Behandlung von Spaltgasen bei der Gewinnung von Ethylen. | |
DE3684825D1 (de) | Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit. | |
ATE446099T1 (de) | N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie | |
ATE55265T1 (de) | Vorrichtung zur behandlung von schrammen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: NOVASEARCH AG, ZUG, CH |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |